American Kidney Fund (AKF) Company Profile
Background
Founded in 1971, the American Kidney Fund (AKF) is a leading nonprofit organization dedicated to combating kidney disease and enhancing the lives of those affected. AKF's mission is to fight kidney disease on all fronts, providing comprehensive programs that support individuals from prevention through post-transplant living. The organization addresses early detection, disease management, financial assistance, clinical research, innovation, and advocacy, impacting more lives than any other kidney-focused nonprofit.
Key Strategic Focus
AKF's strategic objectives encompass:
- Patient Assistance Programs: Offering financial aid to dialysis and recent transplant patients to cover health insurance premiums and treatment-related expenses not covered by insurance.
- Education and Prevention: Implementing award-winning, evidence-based kidney health education resources to raise awareness and empower individuals at risk for kidney disease.
- Clinical Research: Funding fellowships and research initiatives to advance nephrology and improve patient care.
- Advocacy: Influencing public policy and legislation to improve the lives of those living with kidney disease and living organ donors.
Financials and Funding
In the fiscal year ending December 31, 2023, AKF reported:
- Total Revenue: $352.9 million
- Total Expenses: $284.3 million
- Net Assets: $154.4 million
- Program Percentage: 96% of expenses allocated to programs
- Cost to Raise $100: $3
AKF's funding primarily comes from private donations, with 97 cents of every donated dollar invested directly into programs and services.
Pipeline Development
While AKF is not a pharmaceutical company with a product pipeline, it actively supports research and development in nephrology through its Clinical Scientist in Nephrology (CSN) fellowships. Since 1989, these fellowships have funded young researchers conducting prevention and outcomes research, contributing to advancements in kidney disease treatment and management.
Technological Platform and Innovation
AKF leverages various technological platforms to enhance its outreach and operational efficiency:
- Educational Resources: Developing online courses and webinars for healthcare professionals and the public to promote kidney health awareness.
- Digital Engagement: Utilizing social media platforms to disseminate information and engage with the community.
- Data Analytics: Employing data-driven approaches to assess program effectiveness and inform strategic decisions.
Leadership Team
- LaVarne A. Burton: President and CEO since 2005, leading AKF's mission to fight kidney disease and help people live healthier lives.
- Tara Bunch: Executive Vice President and Chief Operating Officer, overseeing AKF's operations and program implementation.
- Julie Puzzo: Chief Development Officer, responsible for fundraising and donor relations.
Leadership Changes
As of the latest available information, there have been no recent significant changes or appointments within AKF's leadership team.
Competitor Profile
Market Insights and Dynamics
The kidney disease nonprofit sector is characterized by organizations focusing on patient support, education, research, and advocacy. The market is driven by the increasing prevalence of kidney disease and the need for comprehensive support services.
Competitor Analysis
- National Kidney Foundation (NKF): Focuses on awareness, prevention, and treatment of kidney disease, offering programs similar to AKF.
- Arthritis Foundation: While primarily focused on arthritis, it shares similarities in providing patient support and advocacy.
- American Liver Foundation: Concentrates on liver diseases but operates in a similar nonprofit healthcare space.
Strategic Collaborations and Partnerships
AKF collaborates with various corporate partners to enhance its programs and services. The 2024 class of corporate members includes:
- Champion Level: Amgen, Inc., Boehringer Ingelheim and Eli Lilly and Company, GSK plc, Novartis Pharmaceutical Corporation, Travere Therapeutics, Inc., and Vertex Pharmaceuticals, Inc.
- Patron Level: Alexion Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Ardelyx, Inc., AstraZeneca plc, Calliditas Therapeutics AB, Otsuka America Pharmaceutical, Inc., Pfizer Inc., PhRMA, and Spherix Global Insights.
- Advocate Level: Apellis Pharmaceuticals, Inc., Aurinia Pharmaceuticals Inc., Bayer U.S. LLC, Biotechnology Innovation Organization, Hansa BioPharma AB, Human Immunology Biosciences (HI-Bio), and Novo Nordisk A/S.
- Friend Level: Merck and Co. and PicnicHealth.
These partnerships provide essential support, enabling AKF to develop, expand, and sustain programs that positively impact those affected by kidney disease.
Operational Insights
AKF's strategic considerations include:
- Program Efficiency: Maintaining a high program percentage (96%) to ensure donor contributions are effectively utilized.
- Transparency and Accountability: Achieving 21 consecutive 4-star ratings from Charity Navigator and a Platinum Seal of Transparency from Candid.
- Workplace Excellence: Recognized as a top nonprofit workplace, reflecting a commitment to employee satisfaction and organizational culture.
Strategic Opportunities and Future Directions
AKF aims to:
- Expand Educational Outreach: Increase awareness and prevention efforts through digital platforms and community programs.
- Enhance Research Initiatives: Support innovative research to advance kidney disease treatment and management.
- Strengthen Advocacy Efforts: Influence public policy to improve healthcare access and outcomes for kidney patients.
- Foster Strategic Partnerships: Collaborate with corporate and community partners to amplify impact and reach.
Contact Information
- Website: KidneyFund.org
- Social Media:
- Headquarters: Rockville, Maryland, USA
